🇺🇸 FDA
Pipeline program

anti-CD123 CAR-T treatment

anti-CD123 CAR-T therapy

Phase 1 small_molecule terminated

Quick answer

anti-CD123 CAR-T treatment for Acute Leukemia is a Phase 1 program (small_molecule) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Legend Biotech Corp
Indication
Acute Leukemia
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials